Novartis Pharmaceuticals

East Hanover, New Jersey 07974

0 studies enrolling now · 80 studies all time

What they study most

Age-related Macular Degeneration (AMD), Alzheimer's Disease, BRAF V600 Mutated-Stage III/IV Melanoma, BRAF v600 Mutated Metastatic Melanoma, Chronic Heart Failure, Chronic Myeloid Leukemia, Chronic Phase, Clinically Isolated Syndrome, Diabetes Mellitus, Type 2, Diabetic Nephropathy, Diastolic Dysfunction, Dyslipidemia, Essential Hypertension

Studies at this site

• A Real-world Study of the Safety of Hypertension Medication Therapy in Japanese Patients With Naïve Hypertension — Completed
• Heart Failure Therapy and Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction — Completed
• Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers — Completed
• Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery Registry — Completed
• Therapeutic Management and Use of Resources and Costs of Spinal Muscular Atrophy in Spain — Completed
• Observational Retrospective Study to Assess the Use of Ribociclib in Patients With HR+, HER2- Metastatic Breast Cancer Treated With Chemotherapy — Completed
• Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma — Completed
• Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies — Completed
• Real-World Evaluation of Patient Characteristics and Treatment Patterns Among Patients With CML-CP Treated With Asciminib — Completed
• Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL Study — Completed
• Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying Therapies — Completed
• An Extension Study of Entacapone in Patients With Parkinson's Disease With End-of-dose Wearing-off. This Study is Not Recruiting in the United States — Completed
• Efficacy and Safety of Valsartan and the Combination of Valsartan and Simvastatin — Completed
• Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension — Stopped early
• Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma Patients — Completed
• Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma — Completed
• Impact of Secukinumab on Clinical and Patient Reported Outcomes in Patients With Psoriasis — Completed
• Role of Sacubitril/Valsartan in Improving Provider Performance in Managing Heart Failure Under Medicare Alternative Payment Models — Completed
• Real-world Evaluation of Brolucizumab for the Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD) (IRIS Study) — Completed
• A Study to Evaluate Efficacy and Safety of LCI699 in Participants With Essential Hypertension — Completed
• Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes — Completed
• Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes — Completed
• Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes — Completed
• Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone — Completed
• Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes — Completed
• A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan. — Completed
• Terbinafine Compared to Griseofulvin in Children With Tinea Capitis — Completed
• Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes — Completed
• A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients — Completed
• Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria — Completed
• Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes — Completed
• Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes — Completed
• "ALOFT - Aliskiren Observation of Heart Failure Treatment": Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure — Completed
• Clinical Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Hydrochlorothiazide in Patients With Essential Hypertension. — Completed
• A Clinical Study to Compare an Aliskiren Based Hypertensive Regimen With a Ramipril Based One Followed by a Randomized Withdrawal. — Completed
• A Clinical Study to Evaluate the Safety and Efficacy of Aliskiren Alone and in Combination With Ramipril in Hypertensive, Diabetic Patients. — Completed
• Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure — Completed
• Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes — Completed
• Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes — Completed
• Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes — Completed
• Safety and Efficacy of Nateglinide in Patients With Type 2 Diabetes Already Taking Insulin Glargine, Metformin and/or Pioglitazone or Rosiglitazone — Completed
• Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes — Completed
• Atrial Fibrillation Feasibility Certoparin Trial - AFFECT — Completed
• Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes — Completed
• Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension — Completed
• A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia — Completed
• A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg — Completed
• A Safety and Efficacy Trial of the Combination of Aliskiren / Hydrochlorothiazide (HCTZ)(300/12.5 mg and 300/25 mg) Compared to Aliskiren 300 mg in Hypertensive Patients — Completed
• Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes — Completed
• Safety/Efficacy of Combo Therapy With Aliskiren & Hydrochlorothiazide vs Therapy With Hydrochlorothiazide Alone in Patients With Hypertension — Completed